Search results for "macular edema"
showing 10 items of 62 documents
Classifying DME vs Normal SD-OCT volumes: A review
2016
International audience; This article reviews the current state of automatic classification methodologies to identify Diabetic Macular Edema (DME) versus normal subjects based on Spectral Domain OCT (SD-OCT) data. Addressing this classification problem has valuable interest since early detection and treatment of DME play a major role to prevent eye adverse effects such as blindness. The main contribution of this article is to cover the lack of a public dataset and benchmark suited for classifying DME and normal SD-OCT volumes, providing our own implementation of the most relevant methodologies in the literature. Subsequently, 6 different methods were implemented and evaluated using this comm…
Classification of SD-OCT Volumes with LBP: Application to DME Detection
2015
International audience; This paper addresses the problem of automatic classification of Spectral Domain OCT (SD-OCT) data for automatic identification of patients with Diabetic Macular Edema (DME) versus normal subjects. Our method is based on Local Binary Patterns (LBP) features to describe the texture of Optical Coherence Tomography (OCT) images and we compare different LBP features extraction approaches to compute a single signature for the whole OCT volume. Experimental results with two datasets of respectively 32 and 30 OCT volumes show that regardless of using low or high level representations, features derived from LBP texture have highly discriminative power. Moreover, the experimen…
Classification of SD-OCT Volumes Using Local Binary Patterns: Experimental Validation for DME Detection
2016
International audience; This paper addresses the problem of automatic classification of Spectral Domain OCT (SD-OCT) data for automatic identification of patients with Diabetic Macular Edema (DME) versus normal subjects. Optical Coherence Tomography (OCT) has been a valuable diagnostic tool for DME, which is among the most common causes of irreversible vision loss in individuals with diabetes. Here, a classification framework with five distinctive steps is proposed and we present an extensive study of each step. Our method considers combination of various pre-processings in conjunction with Local Binary Patterns (LBP) features and different mapping strategies. Using linear and non-linear cl…
Type 1 macular telangiectasia
2018
L’identification à l’examen clinique de petites dilatations anévrismales et d’ectasies paracentrales fait évoquer le diagnostic de télangiectasies maculaires. Celles-ci sont le plus souvent secondaires à une pathologie, notamment au diabète, aux occlusions veineuses, aux vascularites, à un néovaisseau choroïdien de type 3, etc. Le contexte et le reste de l’examen identifieront généralement l’affection primitive. Les télangiectasies maculaires de type 1 (MacTel 1) sont idiopathiques sans cause retrouvée. Ce sont des affections rares, en grande majorité unilatérales, touchant préférentiellement l’homme d’âge moyen (1).
Macular edema: Miscellaneous.
2010
International audience; Abstract. This article provides the reader with practical information to be applied to the various remaining causes of macular edema. Some macular edemas linked to ocular diseases like radiotherapy after ocular melanomas remained of poor functional prognosis due to the primary disease. On the contrary, macular edemas occurring after retinal detachment or after some systemic or local treatment use are often temporary. Macular edema associated with epiretinal membranes or vitreomacular traction is the main cause of poor functional recovery. However, the delay to observe a significant improvement of vision after surgery should be long, as usually observed in tractional …
Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
2021
AbstractWe conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included.…
Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.
2013
Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.
Intravitreal dexamethasone implant for cystoid macular edema and inflammation after scleral buckling
2015
Purpose Cystoid macular edema may occur following scleral buckling and therefore deteriorate the visual outcome. Inflammation may be the major causative factor in the development of postoperative cystoid macular edema. This case demonstrates the effectiveness of a dexamethasone implant as a treatment after the onset of choroidal inflammation and cystoid macular edema 6 months following scleral buckling and having visual acuity restored. Methods A 59-year-old phakic woman treated with scleral buckling for macula-off retinal detachment presented 2 months after surgery with cystoid macular edema with choroidal inflammation. Optical coherence tomography and fluorescein angiography were performe…
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
2011
Patricia Udaondo1,2, Salvador Garcia-Delpech1,3, David Salom1,3, Maria Garcia-Pous1,3, Manuel Diaz-Llopis1,31Nuevo Hospital Universitario y Politecnico La Fe, Valencia, Spain; 2University Cardenal Herrera CEU, Valencia, Spain; 3Faculty of Medicine, University of Valencia, Valencia, SpainPurpose: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen®) injection in the management of refractory macular edema secondary to branch retinal vein occlusion.Methods: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema refractory to either bevacizumab or triamcinolone were treated with intravitreal injection of Pegaptanib s…